We are live on
!
Find out more
EU
Emory University Portfolio holdings
AUM
$160M
1-Year Est. Return
8.57%
This Fund
S&P 500
This Quarter
Est. Return
+4.23%
1 Year Est. Return
+8.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$153M
AUM Growth
+$2.13M
(+1.4%)
Cap. Flow
+$1.9M
Cap. Flow
% of AUM
1.24%
Top 10 Holdings %
Top 10 Hldgs %
48.62%
Holding
52
New
6
Increased
15
Reduced
19
Closed
6
Avg Time Held
5
quarters
Top 10 Avg Time Held
1.2
quarters
Top 20 Avg Time Held
1.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$2.97M |
| 2 |
Solid Biosciences
SLDB
|
+$2.92M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
+$2.86M |
| 4 |
Travere Therapeutics
TVTX
|
+$2.79M |
| 5 |
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
|
+$2.77M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABMD
Abiomed Inc
ABMD
|
+$2.89M |
| 2 |
CORI
Corium International, Inc.
CORI
|
+$2.2M |
| 3 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$2.2M |
| 4 |
KALA BIO
KALA
|
+$2.12M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
+$2.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 53.66% |
| 2 | Financials | 31.55% |
| 3 | Consumer Discretionary | 7% |
| 4 | Industrials | 2.82% |
| 5 | Communication Services | 1.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Berkshire Hathaway Class A
BRK.A
$1.11T
| $37.4M | 24.5% |
117
| – | – |
2016 Q4
7 quarters
|
|
2
JD.com
JD
$36.6B
| $10.4M | 6.79% |
397,578
| – | – |
2017 Q4
3 quarters
|
|
3
Acadia Pharmaceuticals
ACAD
$3.41B
| $4.08M | 2.67% |
196,601
+52,476
| +36% | +$826K |
2015 Q1
14 quarters
|
|
|
MYOV
4
DELISTED
Myovant Sciences Ltd.
MYOV
| $3.37M | 2.2% |
126,800
+3,745
| +3% | +$84.8K |
2017 Q2
5 quarters
|
|
|
GHDX
5
DELISTED
Genomic Health, Inc.
GHDX
| $3.36M | 2.2% |
47,803
-22,667
| -32% | -$1.33M |
2015 Q1
14 quarters
|
|
|
6
Solid Biosciences
SLDB
$737M
| $3.29M | 2.15% |
+4,652
| New | +$2.92M |
2018 Q3
0 quarters
|
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
| $3.2M | 2.09% |
23,015
+934
| +4% | +$117K |
2015 Q2
13 quarters
|
|
|
DBVT
8
DBV Technologies S.A. American Depositary Shares
DBVT
$616M
| $3.11M | 2.04% |
13,845
+2,977
| +27% | +$605K |
2016 Q4
7 quarters
|
|
9
InflaRx
IFRX
$236M
| $3.1M | 2.03% |
90,437
+12,883
| +17% | +$416K |
2018 Q1
2 quarters
|
|
|
BHVN
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $2.96M | 1.94% |
78,838
-11,113
| -12% | -$409K |
2017 Q3
4 quarters
|
|
11
Neurocrine Biosciences
NBIX
$14.5B
| $2.89M | 1.89% |
23,485
-5,334
| -19% | -$605K |
2017 Q2
5 quarters
|
|
|
ONC
12
BeOne Medicines Ltd
ONC
$40.1B
| $2.87M | 1.88% |
16,642
+2,321
| +16% | +$390K |
2017 Q1
6 quarters
|
|
|
ZGNX
13
DELISTED
Zogenix, Inc.
ZGNX
| $2.85M | 1.86% |
57,374
-12,372
| -18% | -$630K |
2016 Q4
7 quarters
|
|
14
Wave Life Sciences
WVE
$682M
| $2.82M | 1.85% |
56,403
-11,522
| -17% | -$520K |
2016 Q4
7 quarters
|
|
|
15
Travere Therapeutics
TVTX
$4.91B
| $2.8M | 1.83% |
+97,510
| New | +$2.79M |
2018 Q3
0 quarters
|
|
|
SGEN
16
DELISTED
Seagen Inc. Common Stock
SGEN
| $2.76M | 1.81% |
35,834
-10,900
| -23% | -$803K |
2015 Q1
14 quarters
|
|
17
Ascendis Pharma A/S
ASND
$15.1B
| $2.73M | 1.78% |
38,486
-2,042
| -5% | -$141K |
2016 Q4
7 quarters
|
|
18
Incyte
INCY
$22.9B
| $2.67M | 1.75% |
38,637
-1,194
| -3% | -$82K |
2015 Q1
14 quarters
|
|
|
ECYT
19
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $2.64M | 1.73% |
148,628
-56,667
| -28% | -$973K |
2018 Q2
1 quarter
|
|
20
BioMarin Pharmaceuticals
BMRN
$10.6B
| $2.61M | 1.71% |
26,940
-3,250
| -11% | -$324K |
2015 Q1
14 quarters
|
|
|
IMMU
21
DELISTED
Immunomedics Inc
IMMU
| $2.61M | 1.71% |
+125,252
| New | +$2.97M |
2018 Q3
0 quarters
|
|
|
MNTA
22
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $2.58M | 1.69% |
+98,084
| New | +$2.65M |
2018 Q3
0 quarters
|
|
|
SAGE
23
DELISTED
Sage Therapeutics
SAGE
| $2.54M | 1.66% |
17,998
+2,503
| +16% | +$386K |
2018 Q1
2 quarters
|
|
|
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
| $2.45M | 1.6% |
202,726
+20,683
| +11% | +$289K |
2017 Q2
5 quarters
|
|
|
25
Madrigal Pharmaceuticals
MDGL
$10.9B
| $2.44M | 1.6% |
+11,391
| New | +$2.86M |
2018 Q3
0 quarters
|
|
Similar funds
WH
CPW
NWS
SGM
CI
SA
SH
HA
Emory University's Q3 2018 Portfolio in Review
As of Q3 2018, Emory University held 52 positions worth $153M, up 1.4% from $151M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Emory University's Q3 2018 filing shows 6 new, 15 increased, 19 reduced and 6 closed positions. Its largest new stake was Immunomedics Inc: 125,252 shares worth $2.61M. The largest sale was Abiomed Inc, an estimated $2.89M.
By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 52% a quarter earlier, followed by Financials and Consumer Discretionary.
- Emory University's largest Q3 2018 buy was Immunomedics Inc: 125,252 shares worth $2.61M.
- Emory University added most to La Jolla Pharmaceutical Company in Q3 2018, an estimated $897K increase.
- Emory University's biggest Q3 2018 reduction was Genomic Health, Inc., cutting an estimated $1.33M.
- Emory University fully exited Abiomed Inc in Q3 2018, selling an estimated $2.89M.
- Emory University's ten largest holdings make up 49% of its $153M portfolio in Q3 2018.
- Emory University opened 6 new positions and closed 6 in Q3 2018.
- Emory University's portfolio value rose 1.4% quarter-over-quarter to $153M.
Based on Emory University's 13F filing for Q3 2018, filed 14 Nov 2018.